Wet age-related macular degeneration (wet AMD) is a progressive eye disease in which abnormal, fragile blood vessels grow under the macula and leak fluid or blood, leading to irreversible central vision loss if not treated. In many patients, untreated wet AMD can progress to legal blindness within months to a few years. Wet AMD primarily affects older adults, with prevalence rising steeply with age. Recent analyses suggest that approximately 1–3% of individuals aged 75 years and older are affected, with hundreds of thousands of patients living with wet AMD in the US alone and substantial numbers of new diagnoses each year (1-3). As populations age, the overall burden of wet AMD is expected to increase further over the coming decades. The current standard of care for wet AMD is based on intravitreal anti-VEGF therapies. These often require 6–10 injections in the first year, followed by ongoing injections in subsequent years, resulting in a long-term treatment burden for patients. Beyond the risk of complications from frequent injections, this regimen places significant pressure on healthcare services and on patients with their caregivers who must attend regular, time-consuming clinic visits. Despite intensive treatment, an estimated 25–35% of patients with more aggressive disease have partial or inadequate responses and remain at risk of progressive, irreversible vision loss. Given these limitations, there is a strong unmet need for more durable, disease-modifying therapies. A broad R&D pipeline is investigating new molecular targets and innovative delivery technologies, including gene therapies designed to drive long-term intraocular expression of anti-VEGF or VEGF-targeting molecules. Gene therapies could thereby reduce or eliminate the need for repeated injections. Later-stage (pivotal Phase 3) AAV-based gene therapy candidates include 4D-150 (4D Molecular Therapeutics), ABBV-RGX-314 (sura-vec, Regenxbio/AbbVie) and ADVM-022 (ixo-vec, Adverum). These candidates ha...

Explore the exciting world of Cadence Design Systems (NASDAQ: CDNS) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Dec. 10, 2025. The video was published on Jan. 26, 2026. Should you buy stock in Cadence Design Systems right now? Before you buy stock in Cadence Design Systems, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Cadence Design Systems wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $464,439!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,150,455!* Now, it’s worth noting Stock Advisor’s total average return is 949% — a market-crushing outperformance compared to 195% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of January 26, 2026. Anand Chokkavelu has no position in any of the stocks mentioned. Jason Hall has no position in any of the stocks mentioned. Rick Munarriz has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cadence Design Systems. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

格隆汇1月27日｜美国国土安全部助理部长McLaughlin：美国边境巡逻队“总指挥”格雷戈里·博维诺并未被解除职务。

委内瑞拉代总统德尔西·罗德里格斯回应美国官员的言论称，她不惧威胁，也不会服从外部命令。 委内瑞拉代总统德尔西·罗德里格斯周日在安索阿特吉州向国家石油公司员工发表演讲时表示，委内瑞拉已经“受够了”美国干涉。 “华盛顿对委内瑞拉政界人士的指手画脚该停止了，委内瑞拉的政治分歧和冲突应当由我们自己解决，”罗德里格斯对人群宣称，“外国势力的干预也该到此为止。” 随着石油产业改革方案遭遇公共部门和左翼政党抵制，罗德里格斯及其兄弟、国民议会主席豪尔赫·罗德里格斯于周末加强了言辞力度。 在遭到批评后，这对兄妹在拉十字港炼油厂会见了委内瑞拉国家石油公司的工人。此前政府提出的一系列石油改革方案将打破国家垄断，允许私营企业开采和销售该国庞大石油储备中的原油。 这些言论凸显了政府为平息国内对委内瑞拉石油产业改革反对声浪所做的努力。在美方前所未有的干预下，议员们正准备就旨在吸引外资的改革方案进行表决。 尽管罗德里格斯发表上述言论，但仍有迹象表明委内瑞拉政府正持续向华盛顿示好，包括在尼古拉斯·马杜罗被抓捕后自1月8日启动的更广泛进程中释放数十名政治犯。据非政府组织Justicia， Encuentro y Perdón统计，此后已有约229名政治犯获释，但仍有数百人身陷囹圄。 责任编辑：王永生

《科创板日报》1月27日讯 今日科创板早报主要内容有：千问Qwen3大模型在轨部署成功；人形机器人直连低轨高通量卫星试验成功；宇树科技成为2026年春晚机器人合作伙伴。 《科创板日报》主播小K为您播报。 市场动态 全国科技工作会议：科技革命和产业变革越是深入发展 越要努力抢占国际竞争制高点 全国科技工作会议26日在京召开。中共中央政治局常委、中央科技委员会主任丁薛祥出席会议并讲话。丁薛祥表示，科技革命和产业变革越是深入发展，越要努力抢占国际竞争制高点，牢牢掌握科技竞争主动权。科技工作越是取得进步，越要保持清醒头脑，推动科技事业发展行稳致远。 微软发布最新人工智能芯片 旨在减少对英伟达的依赖 微软公司推出其第二代人工智能（AI）芯片。这是该公司努力提高服务效率、并提供英伟达硬件替代方案的核心举措。这款名为Maia 200的芯片由台积电代工，目前正陆续进入微软位于爱荷华州的数据中心，下一站将部署在凤凰城地区。1月26日，微软邀请开发者开始使用Maia的控制软件，但目前尚不清楚Azure云服务的用户何时能正式使用基于该芯片运行的服务器。 千问Qwen3大模型在轨部署成功 在2026年1月26日由中国信通院组织的“星算·智联”太空算力研讨会上，国星宇航执行副总裁王亚波披露，2025年11月，国星宇航成功将千问Qwen3大模型部署至“星算”计划01组太空计算中心，这是全球首次将通用大模型从地面上注至在轨运行的卫星，实现在轨部署。随后，千问大模型在太空中成功执行多次端到端推理任务，问题从地面上传至卫星，由大模型完成在轨推理，并将结果数据回传地面，全流程耗时不到2分钟。 人形机器人直连低轨高通量卫星试验成功 记者从第三届北京商业航天产业高质量发展推进会获悉，北京人形机器人创新中心“具身天工”机器人成功连接银河航天新型翼阵合一互联网卫星，实现了低轨高通量卫星联网同步传输机器人视觉数据。据了解，这是具身智能人形机器人直连低轨卫星的全球首次成功试验，也是我国首次新型相控阵平板低轨互联网卫星实现多终端、多链路的连接，验证了无地面网络支撑下的稳定作业能力，这一突破为机器人户外场景可靠通信及产业跨界融合提供了实践支撑。 百度智能云上调AI相关收入增速目标至200% 在近期的内部战略会上，百度智能云高管定调，2026年AI相关收入目标增速从100%上调至200%，全员力拼高增长，在AI云市场全...

(RTTNews) - Enterprise Financial Services Corp. (EFSC) released a profit for its fourth quarter that Increases, from the same period last year in line with the Street estimates. The company's bottom line came in at $53.86 million, or $1.45 per share. This compares with $47.90 million, or $1.28 per share, last year. Excluding items, Enterprise Financial Services Corp. reported adjusted earnings of $1.36 per share for the period. Analysts on average had expected the company to earn $1.36 per share. Analysts' estimates typically exclude special items. The company's revenue for the period rose 15.9% to $193.58 million from $167.00 million last year. Enterprise Financial Services Corp. earnings at a glance (GAAP) : -Earnings: $53.86 Mln. vs. $47.90 Mln. last year. -EPS: $1.45 vs. $1.28 last year. -Revenue: $193.58 Mln vs. $167.00 Mln last year. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

当地时间1月26日，美股三大指数在波动中集体收涨，道琼斯指数上涨313.69点，涨幅0.64%，报49412.40点；标普500指数涨0.50%，报6950.23点；纳斯达克指数涨0.43%，报23601.36点。 市场内部呈现出科技股与芯片股走势分化、避险资产价格剧烈波动的复杂图景。贵金属市场上，现货 白银 盘中一度大涨14%突破117美元，创下历史新高；现货 黄金 也站上5110美元高点。 美股大型科技股多数上涨 美股大型科技股多数上涨，推动指数上行。苹果公司表现抢眼，股价上涨近3%，收于255.410美元。消息面上，苹果计划在2月宣布新版Siri，并与谷歌达成合作，放弃完全依赖自研模型的路线。Meta Platforms上涨逾2%，谷歌母公司Alphabet上涨逾1%，微软小幅上涨0.93%。但亚马逊和英伟达小幅 下跌 ，特斯拉则大跌逾3%，显示市场对电动汽车行业的担忧。值得注意的是，本周是财报季的关键时期，微软、Meta、特斯拉和苹果等科技巨头将陆续发布财报，投资者正密切关注 人工智能 相关业务的进展和盈利指引。 芯片股成为当日的软肋。费城 半导体 指数 下跌 0.39%，英特尔重挫逾5%，该股上周五已暴跌17%，因公司发布的一季度营收指引低于预期。超威半导体（AMD）跌逾3%，美光科技跌逾2%。芯片股的疲软反映出市场对半导体行业需求放缓的忧虑。与此相对，中概股多数 下跌 ，纳斯达克中国金龙指数收跌0.63%。 热门中概股中，禾赛科技跌逾10%，小马智行跌逾5%，百度集团跌超3%，小鹏汽车跌超2%。但金山云涨逾8%，虎牙涨逾7%，显示部分中概股仍具韧性。 贵金属市场上演“过山车”行情 现货黄金一度大涨2.5%，突破5100美元/盎司，创下历史新高；现货白银更是飙升近14%，最高触及117.74美元/盎司。然而，获利回吐压力导致金银价格大幅回调，黄金最终回落至5000美元关口附近，白银涨幅收窄至约103美元/盎司。1月27日亚洲早盘，国际黄金高开后拉升，白银震荡反弹，盘中涨逾2%。 分析指出，贵金属的强势受地缘政治风险和避险情绪驱动，但技术性回调风险加剧。中长期来看，黄金已逐渐从避险资产转型为全球资产配置核心工具，央行购金和去美元化趋势支撑其前景。 此外，市场关注美联储即将召开的议息会议。尽管普遍预期利率将维持不变，但投资者期待鲍威尔的讲话能为降息路径提供线索...

韩元早盘下跌，此前美国总统唐纳德·特朗普威胁要将韩国商品的关税全面提高至25%，而他给出的理由是该国国会尚未就双方去年达成的贸易协定立法。美元/韩元一度上涨0.7%至1452.25。该货币对上个交易日收跌1.5%。 责任编辑：王永生

导读： 财联社1月27日投资避雷针，近日，A股及海外市场潜在风险事件如下。国内经济信息方面包括：1）马化腾评豆包手机，用外挂方式把手机和电脑屏幕录屏传到云端“极不安全、不负责任”；2）机构预计2026年全球磷酸锰铁锂产量达7万吨，去年为2.85万吨；公司方面重点关注包括：1）东方日升预计2025年净亏损23亿元-29亿元，光伏产品未直接向商业航天卫星公司供货；2）20CM涨停两连板瑞华泰公告，2025年航天领域营收占比不足1%；海外市场重点关注包括：1）黄金与白银在刷新历史高点后大幅回调；2）受CPU、存储器价格同步上涨压力，机构预估一季度笔电出货量将季减14.8%。 经济信息 1、腾讯董事会主席马化腾在一年一度的员工大会，谈及了过去一年的外卖大战、AI大战、以及豆包手机和阿里千问，还谈及了包括云、游戏、文档、腾讯新闻、TME（腾讯音乐娱乐）、应用宝等在内的多项腾讯旗下业务。他说，AI是腾讯过去重点投入的一大业务，而云业务已实现盈利，腾讯游戏业务“强得可怕”。而对于“豆包”通过底层接入手机、协助用户执行操作的模式，他则明确表达了反对，称用外挂方式把用户手机和电脑屏幕录屏传到云端，“极不安全、不负责任”，腾讯对此“旗帜鲜明反对”。 (第一财经) 2、碳酸锂期货高开低走，主力合约LC2605下跌6.65%至165680元/吨，持仓量减少2.2万手至41.67万手。随着碳酸锂期货价格走高，市场分歧开始加剧，贸易商进入捂货不出状态，下游采购积极性也随之下调。在今日价格上行时，部分企业忍不住在高位点价买货，结果买完就后悔。一位材料厂的采购负责人表示，现在长协月均价较低，当前的价格处于相对高位，担心过早采购买到高价货，目前公司仍处于观望状态，希望等到心仪的价格再加大采购力度。 (新华财经) 3、上海国际能源交易中心发布公告，2026年1月26日，一组实际控制关系账户在相关合约上账户组日内开仓交易量超限第1次达到上海国际能源交易中心（以下简称上期能源）处理标准。上述客户交易行为违反《上海国际能源交易中心异常交易行为管理细则》第16条之规定，上期能源决定对相关客户在相应合约上采取限制开仓的监管措施。 4、据统计，2025年全球磷酸锰铁锂产量2.85万吨，同比增长206.5%。随着在新能源汽车、数码消费、锂电两三轮车市场地应用持续深入，预计到2026年产量增至7万吨，到2030年产量...

Source: Bloomberg, 4:42

It doesn't look like the company will end up in the arms of an acquirer soon, after all. Monday was generally a good day for the stock market; nevertheless, some titles landed in negative territory. One that plunged well into the red was clinical-stage biotech Revolution Medicines (RVMD 16.88%), which took a nearly 17% hit to its share price after a media report published over the weekend. Buyout blues On Sunday, The Wall Street Journal wrote that Merck was no longer in discussions with Revolution regarding an acquisition. Investors were understandably crushed by this apparent news, as hot speculation had it that the two companies were discussing a deal worth tens of billions of dollars. Citing unidentified "people familiar with the matter," the Journal said that the talks stalled after Revolution and Merck failed to agree on the price of a buyout. The financial newspaper's sources added that this isn't necessarily the end of Merck's pursuit, as the discussions between the two companies could resume. Merck is not the only enterprise reported to be interested in acquiring Revolution; earlier this month, the Journal wrote that AbbVie and other pharmaceutical companies were also in the hunt. AbbVie subsequently denied it was pursuing Revolution. Expand NASDAQ : RVMD Revolution Medicines Today's Change ( -16.88 %) $ -19.85 Current Price $ 97.78 Key Data Points Market Cap $23B Day's Range $ 92.50 - $ 99.51 52wk Range $ 29.17 - $ 124.49 Volume 10M Avg Vol 3.3M A prized and pricey asset I'd bet my bottom dollar that the speculation about multiple potential suitors is true. Revolution's specialty is the development of oncology drugs, which remains a very hot, high-interest segment of the pharmaceutical industry. What's more, the company's leading drug candidate, daraxonrasib, is currently in Phase 3 clinical trials for the treatment of pancreatic and non-small cell lung cancer. So even if Merck goes away completely, I think Revolution will sell for a handsome premium if it ...

Trump Threatens To Raise Tariffs On South Korean Goods To 25%; Won Slides Here we go again. President Trump threatened to hike tariffs on goods from South Korea to 25% from 15%, citing in a Truth Social post what he said was the failure of the country’s legislature to codify the trade deal the two nations reached last year, a failure which was obvious from miles away as the terms of the trade deal require Korea to invest hundreds of billions - which it doesn't have - in the US. The new rate would apply to autos, lumber, pharmaceutical products and “all other Reciprocal TARIFFS," he wrote in a social media post. It probably would not apply to memory chips which are already the most expensive thing on plant earth, at least until the RAM producing cartel starts to, well, producing RAM again. If implemented, the move could have wide-ranging effects on major South Korean companies that export to the US, such as Hyundai Motor, which sent 1.1 million vehicles to America in 2024. As Bloomberg notes, Trump’s announcement marks his latest move to ratchet up trade tensions with allies. In recent weeks, he has threatened to raise duties on Canadian products to 100% if Ottawa signed a trade deal with China (it then promptly said it would not) and to slap new charges on European countries’ goods over his quest to seize control of Greenland. The USDKRW gapped up 0.7% to 1452 on the news, amid thin liquidity before the local market open. Tyler Durden Mon, 01/26/2026 - 19:16

百度智能雲擬將AI相關收入增速目標上調一倍至200% AASTOCKS.com

格隆汇1月27日｜华西证券指出，中长期视角下，对比A股历次牛市，本轮行情仍处中段，“慢牛”趋势有望延续。行业配置上，建议关注：（1）科技产业行情扩散：如AI算力、AI应用、机器人、太空光伏、存储、港股互联网等；（2）受益于“反内卷”与涨价方向，如化工、有色金属等；（3）年报业绩预告高增行业：如电子、机械设备、医药等。

Pacific Investment Management Co. is holding fast to its conviction in Japan’s 30-year government bonds after last week’s rout, joining a growing pool of investors who see value in the nation’s debt market. Current yield levels present attractive investment opportunities, the money manager said. Last week, fears of fiscal excess by Prime Minister Sanae Takaichi’s administration wiped out $41 billion from the bond market and triggered a selloff elsewhere. Higher yields offer the potential for capital gains if interest rates fall and serve as a hedge against economic shocks, volatility in equities or a sharp appreciation in the yen, Pimco added. “We maintain a preference for the long-end of the curve, such as 30-year JGBs,” Tomoya Masanao, Pimco’s head of Asia-Pacific portfolio management, wrote in an outlook report . “While concerns about fiscal risks persist, the steepness of the yield curve and incentives for the Ministry of Finance to limit long-end issuance support this positioning.” The call mirrors the view of investors including Sumitomo Mitsui Financial Group Inc. and RBC BlueBay Asset Management , and suggests that investors have grown accustomed to gyrations in Japan’s bond market after years of accommodative policy kept yields pinned near zero. Traders are bracing for swings to pick up again after a period of calm, as the nation gears up for an election on Feb. 8 and talk of intervention buffets the yen. Pimco, one of the world’s biggest bond houses, was similarly optimistic about JGBs after a chaotic selloff in mid-2025. Back then, the money manager argued that the possibility of more quantitative tightening by the Bank of Japan could be a good thing, since it would relieve pressure on the long-end of the curve, where the central bank is less active. The money manager expects the BOJ to continue normalizing policy gradually and potentially raise the policy rate by a quarter to half a percentage point toward 1% to 1.25% over the coming year. The central ba...

The Fatal Limits Of The Technocrat Class Authored by Charles Hugh Smith via OfTwoMinds blog, Goliath dies not because collapse occurs, but because scale mistakes itself for life. What survives was never his. This guest essay by longtime correspondent 0bserver speaks to a dynamic woven into all of my work: the intrinsic impossibility of fixing what technocratic management broke with more technocratic management. Attempts to do so result in doing more of what's failed , with fatal consequences for the systems being "fixed," as the technocratic elite holds the power to impose policies but is immune to the consequences of the failure of those policies. Those fall on the system, which then veers into incoherence and Model Collapse. I've been reading Luke Kemp's Goliath's Curse: The History and Future of Societal Collapse with care, because the book is serious, well-researched, and written from within institutions that spend their days thinking about systemic fragility. Kemp is not unserious, nor is he shallow. His diagnosis of elite failure, complexity, inequality, and institutional overreach aligns with much of what many of us have been warning about for years. Where I think the book ultimately fails, however, is not in what it sees--but in what it cannot see from the altitude at which it operates. Kemp's collapse framework is managerial. Collapse is treated as a system-level pathology to be prevented through coordination, governance, and institutional reform. This makes sense given his professional formation and affiliations, but it creates a blind spot that becomes more consequential the longer one reads: continuity is assumed, not explained. The book speaks fluently about sustainability, inequality, elite capture, and long-term risk. Yet it does not seriously engage with inheritance--not inheritance as wealth alone, but inheritance as transmission: skills, trades, family structure, norms, fertility, competence, and responsibility carried forward across generations. S...

来源：智通财经网 美国政府提议明年将联邦医疗保险（Medicare）私人计划的支付费率维持在当前水平，这一消息令投资者大失所望，美国主要保险公司股价应声暴跌。 周一美股盘后，联合健康（UNH.US）股价一度暴跌9.3%，西维斯健康（CVS.US）跌幅最高达10%，哈门那（HUM.US）更是重挫逾15%。 美国医疗保险和医疗补助服务中心（CMS）在公告中表示，预计2027年联邦医保优势计划（Medicare Advantage）的支付费率仅将上调0.09%，远低于分析师此前预期的高达6%的增幅。 该中心主任Mehmet Oz在公告中称：“本次拟议的支付政策，核心是让联邦医疗保险优势计划更好地服务于参保人群。” 对于本就因医疗成本攀升及所谓的政府拨款不足而利润承压的联邦医保承保商而言，此次费率调整几乎意味着零增长。不过，最终费率将在未来数月内确定，后续仍有上调可能。 支付费率对联合健康、西维斯健康和哈门那等大型保险商至关重要。联邦医保优势计划作为面向老年人的联邦医保私营版本，过去十多年一直是保险行业增长的重要引擎。但近年来该业务盈利能力不断下降，多项新支付规则侵蚀利润后，已有多家保险商股价遭遇断崖式下跌。 支付费率提高能帮助保险公司覆盖医疗成本、提升老年客户福利并增厚利润，而小幅上调则会直接压缩企业利润率。 按照此次拟议费率，2027年联邦医疗保险计划的总支付额较今年仅增加7亿美元，对于这个通常以数十亿美元级别实现支付增长的行业而言，这一幅度可谓微乎其微。 CMS同时表示，正拟定多项配套政策，旨在“进一步提高支付核算精准度、保障参保人选择权、确保联邦医疗保险参保人能获得价格合理的保险保障”。 据为美国国会提供咨询的联邦医疗保险支付咨询委员会测算，2024年联邦医疗保险优势计划的参保人数达近3400万，占符合参保条件人群的半数以上，美国政府向相关计划的支付总额达4940亿美元。 该委员会估计，与传统医保项目相比，2025年通过联邦医保优势计划覆盖人群将使政府成本增加20%，约合840亿美元。该机构长期呼吁改革以降低对相关计划的支付额，而特朗普政府医保部门官员近期发布的一份报告则指出，两类计划的支付差额可能小于预估。 保险业相关协会则反驳私人计划收费过高的说法，强调联邦医保优势计划为老年人提供了更优价值和更高效的医疗服务。 近年来，联邦医疗保险优势计划业务的经营难度不断加大...

Shares in South Korean automakers slide after Trump post on raising tariffs Reuters

韩国财政部周二表示，政府将与美国保持密切沟通，以推进一项旨在支持韩国在美投资计划的特别法案的相关立法工作。此前，美国总统唐纳德·特朗普突然宣布将提高对韩国的对等关税和汽车关税。 “我们目前正努力了解美方的意向，”韩国经济财政部表示，“接下来，我们将与美国政府进行沟通，向其解释在国民议会关于该法案的讨论中的进展情况。” 此前美国总统特朗普在社交媒体上发文称，他将把对韩国的“对等”关税和汽车关税从 15% 提高到 25%，并指责韩国立法机构迟迟未完成实施两国双边贸易协议的国内程序。 去年11月，韩国执政的共同民主党提交了一份特别法案，以支持韩国向美国承诺的3500亿美元投资，这是两国关税协议的一部分。 韩国财政部表示，计划在当天晚些时候举行的财政部长与国会财政委员会主席的会晤中，请求国会配合该法案的通过。 责任编辑：于健 SF069

格隆汇1月27日｜国恩股份公告，1月27日，公司按照有关规定在香港联交所网站刊登并派发本次发行并上市H股招股说明书。公司本次全球发售H股发行股数为3000万股。公司本次H股发行的价格区间初步确定为34港元至42港元。公司H股香港公开发售于1月27日开始，预计于1月30日结束，并预计于2月2日前（含当日）公布发行价格。

金价上涨，连续第二天保持在每盎司5000美元上方。美元走软助其延续了地缘政治风险和投资者抛售主权债券及货币所推动的涨势。 金价周二早盘一度上涨逾1%，连续第七个交易日走高。彭博美元即期指数隔夜跌至近四年来的最低水平，从而增强了大多数买家的黄金购买力，同时美国总统唐纳德·特朗普威胁要上调韩国商品关税税率至25%。 黄金今年以来已累计上涨近17%，这反映了投资者抛售货币和主权债券的所谓“贬值交易”卷土重来。上周日本国债大跌，是投资者拒绝大规模财政支出的最新例证。 截至北京时间07：56，金价涨0.8%，至每盎司5050.01美元。银价上涨3.5%，至每盎司107.44美元，前一交易日其在创下117.71美元的历史新高后回吐了涨幅。铂金和钯金亦走高，而彭博美元指数在前一交易日下跌0.4%之后持稳。 责任编辑：王永生

英矽智能（HK3696）1月27日早间在港交所公告，英矽智能（HK3696）已与齐鲁制药集团及其附属公司上海齐鲁制药研究中心，达成药物研发战略合作并签署相关协议。透过该合作，双方将依托英矽智能（HK3696）自有Pharma.AI解决方案，针对特定靶点开展小分子抑制剂合作开发，关注心血管与代谢类疾病领域管理。根据该协议的条款，英矽智能（HK3696）将利用自主搭建的Pharma.AI平台，关注用于代谢疾病领域的新颖小分子药物设计与优化，齐鲁制药将负责后续开发与商业化工（850102）作。该协议总额超9.31亿港元，包含开发和销售里程碑付款，以及单位数的后续净销售额分成。

格隆汇1月27日｜据央视，当地时间1月27日凌晨，法国国民议会通过一项禁止15岁以下未成年人使用社交媒体的法案。根据法案内容，由在线平台提供的社交网络服务，将禁止15岁以下未成年人使用。法国总统马克龙也在27日凌晨发文强调，国民议会通过这一法案是一个重要里程碑。

现代汽车 领跌韩国汽车股，此前特朗普威胁加征新关税。现代汽车股价周二开盘时下跌4%，此前美国总统特朗普在社交媒体上发文称，他将把对包括汽车在内的韩国商品征收的关税从15%提高到25%。 兄弟汽车制造商起亚公司和关联公司现代摩比斯的股价也分别下跌了约3.4%和5%。 责任编辑：王永生

China’s Anta Sports Products Ltd. has agreed to buy a stake of about 29% in Puma SE for €1.5 billion ($1.8 billion), making it the German sports brand’s biggest shareholder. The agreement will see Anta buy about 43 million Puma shares from Artémis, the holding compay of France’s billionaire Pinault family, for €35 each. Puma closed Monday at €21.63. Puma’s shares have fallen 32% over the past 12 months, giving the company a market capitalization of €3.2 billion. Fujian-based Anta is down 7% in Hong Kong over the past 12 months and has a market value of $27.3 billion. The purchase is a key step in the company’s “single-focus, multi-brand, and globalization” strategy, Anta said in a filing to the Hong Kong stock exchange. Bloomberg News reported in November that Anta was among the companies exploring a potential takeover of Puma, and said the firm had been working with an adviser to evaluate a bid. Puma shares jumped the most in years on the news. Read More: China’s Anta Sports Is Said to Weigh Potential Bid for Puma